APO Research
Talk to an analyst

APO RESEARCH · REPORT

Natural Killer Cell Therapy

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

Selected research

Market Outlook & Growth Opportunities

Global Natural Killer Cell Therapy Market Outlook and Growth Opportunities 2026

31 December 2025191 pages

Choose your research edition.

Industry ResearchNatural Killer Cell Therapy Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Natural Killer Cell Therapy Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Natural Killer Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Natural Killer Cell Therapy Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Natural Killer Cell Therapy Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

The Americas natural killer cells therapeutics market share accounted for the highest share 52.3% in 2019.

Based on application, the market is classified into cancer, gastrointestinal diseases and others. The cancer segment accounted for a major share in 2019 (66.99%).

Read the full market overview

Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics and etc. The Top 6 players accounted for 96.66% of the global revenue market share in 2019.

This report provides an overview of the global Natural Killer Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Natural Killer Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Natural Killer Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Natural Killer Cell Therapy market.

Natural Killer Cell Therapy Segment by Company

Nektar Therapeutics

Innate Pharma SA

Affimed

Chipscreen Biosciences

Glycostem Therapeutics

Fate Therapeutics

Dragonfly Therapeutics

Kiadis Pharma

Nkarta Therapeutics

NantKwest

Natural Killer Cell Therapy Segment by Type

NK Cell Therapies

NK Cell Directed Antibodies

Natural Killer Cell Therapy Segment by Application

Cancer

Gastrointestinal Diseases

Others

Natural Killer Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Natural Killer Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Natural Killer Cell Therapy key companies, revenue, market share, and recent developments.

3. To split the Natural Killer Cell Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Natural Killer Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Natural Killer Cell Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Natural Killer Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Natural Killer Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Natural Killer Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Natural Killer Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Natural Killer Cell Therapy industry.

Chapter 3: Detailed analysis of Natural Killer Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Natural Killer Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Natural Killer Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Natural Killer Cell Therapy Industry Trends Table 2. Natural Killer Cell Therapy Industry Drivers Table 3. Natural Killer Cell Therapy Industry Opportunities and Challenges Table 4. Natural Killer Cell Therapy Industry Restraints Table 5. Global Natural Killer Cell Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Natural Killer Cell Therapy Revenue Share by Company (2021-2026) Table 7. Global Natural Killer Cell Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Natural Killer Cell Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Natural Killer Cell Therapy Company, Product Type & Application Table 10. Global Natural Killer Cell Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Natural Killer Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of NK Cell Therapies Table 15. Significant Companies of NK Cell Directed Antibodies Table 16. Global Natural Killer Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Natural Killer Cell Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Natural Killer Cell Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Natural Killer Cell Therapy Sales Value Share by Type (2021-2026) Table 20. Global Natural Killer Cell Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Cancer Table 22. Significant Companies of Gastrointestinal Diseases Table 23. Significant Companies of Others Table 24. Global Natural Killer Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Natural Killer Cell Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Natural Killer Cell Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Natural Killer Cell Therapy Sales Value Share by Application (2021-2026) Table 28. Global Natural Killer Cell Therapy Sales Value Share by Application (2027-2032) Table 29. Global Natural Killer Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Natural Killer Cell Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Natural Killer Cell Therapy Sales Value Share by Region (2021-2026) Table 32. Global Natural Killer Cell Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Natural Killer Cell Therapy Sales Value Share by Region (2027-2032) Table 34. Global Natural Killer Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Natural Killer Cell Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Natural Killer Cell Therapy Sales Value Market Share by Country (2021-2026) Table 37. Global Natural Killer Cell Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Natural Killer Cell Therapy Sales Value Market Share by Country (2027-2032) Table 39. Nektar Therapeutics Company Information Table 40. Nektar Therapeutics Business Overview Table 41. Nektar Therapeutics Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Nektar Therapeutics Natural Killer Cell Therapy Product Portfolio Table 43. Nektar Therapeutics Recent Development Table 44. Innate Pharma SA Company Information Table 45. Innate Pharma SA Business Overview Table 46. Innate Pharma SA Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Innate Pharma SA Natural Killer Cell Therapy Product Portfolio Table 48. Innate Pharma SA Recent Development Table 49. Affimed Company Information Table 50. Affimed Business Overview Table 51. Affimed Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Affimed Natural Killer Cell Therapy Product Portfolio Table 53. Affimed Recent Development Table 54. Chipscreen Biosciences Company Information Table 55. Chipscreen Biosciences Business Overview Table 56. Chipscreen Biosciences Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Chipscreen Biosciences Natural Killer Cell Therapy Product Portfolio Table 58. Chipscreen Biosciences Recent Development Table 59. Glycostem Therapeutics Company Information Table 60. Glycostem Therapeutics Business Overview Table 61. Glycostem Therapeutics Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Glycostem Therapeutics Natural Killer Cell Therapy Product Portfolio Table 63. Glycostem Therapeutics Recent Development Table 64. Fate Therapeutics Company Information Table 65. Fate Therapeutics Business Overview Table 66. Fate Therapeutics Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Fate Therapeutics Natural Killer Cell Therapy Product Portfolio Table 68. Fate Therapeutics Recent Development Table 69. Dragonfly Therapeutics Company Information Table 70. Dragonfly Therapeutics Business Overview Table 71. Dragonfly Therapeutics Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Dragonfly Therapeutics Natural Killer Cell Therapy Product Portfolio Table 73. Dragonfly Therapeutics Recent Development Table 74. Kiadis Pharma Company Information Table 75. Kiadis Pharma Business Overview Table 76. Kiadis Pharma Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Kiadis Pharma Natural Killer Cell Therapy Product Portfolio Table 78. Kiadis Pharma Recent Development Table 79. Nkarta Therapeutics Company Information Table 80. Nkarta Therapeutics Business Overview Table 81. Nkarta Therapeutics Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Nkarta Therapeutics Natural Killer Cell Therapy Product Portfolio Table 83. Nkarta Therapeutics Recent Development Table 84. NantKwest Company Information Table 85. NantKwest Business Overview Table 86. NantKwest Natural Killer Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. NantKwest Natural Killer Cell Therapy Product Portfolio Table 88. NantKwest Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Natural Killer Cell Therapy Product Image Figure 2. Global Natural Killer Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Natural Killer Cell Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Natural Killer Cell Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. NK Cell Therapies Image Figure 8. NK Cell Directed Antibodies Image Figure 9. Global Natural Killer Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Natural Killer Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Natural Killer Cell Therapy Sales Value Share by Type (2021-2032) Figure 12. Cancer Image Figure 13. Gastrointestinal Diseases Image Figure 14. Others Image Figure 15. Global Natural Killer Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Natural Killer Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Natural Killer Cell Therapy Sales Value Share by Application (2021-2032) Figure 18. Global Natural Killer Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Natural Killer Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Natural Killer Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 21. North America Natural Killer Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Natural Killer Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Natural Killer Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Natural Killer Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Natural Killer Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Natural Killer Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 27. South America Natural Killer Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Natural Killer Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Natural Killer Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • NK Cell Therapies
  • NK Cell Directed Antibodies
Applications
  • Cancer
  • Gastrointestinal Diseases
  • Others
Companies covered
  • Nektar Therapeutics
  • Innate Pharma SA
  • Affimed
  • Chipscreen Biosciences
  • Glycostem Therapeutics
  • Fate Therapeutics
  • Dragonfly Therapeutics
  • Kiadis Pharma
  • Nkarta Therapeutics
  • NantKwest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Natural Killer Cell Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Natural Killer Cell Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Natural Killer Cell Therapy Market Dynamics
  1. 2.1 Natural Killer Cell Therapy Industry Trends
  2. 2.2 Natural Killer Cell Therapy Industry Drivers
  3. 2.3 Natural Killer Cell Therapy Industry Opportunities and Challenges
  4. 2.4 Natural Killer Cell Therapy Industry Restraints
3 Natural Killer Cell Therapy Market by Company
  1. 3.1 Global Natural Killer Cell Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Natural Killer Cell Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Natural Killer Cell Therapy Company Ranking (2024-2026)
  4. 3.4 Global Natural Killer Cell Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Natural Killer Cell Therapy Company Product Type and Application
  6. 3.6 Global Natural Killer Cell Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Natural Killer Cell Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Natural Killer Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Natural Killer Cell Therapy Market by Type
  1. 4.1 Natural Killer Cell Therapy Type Introduction
  2. 4.1.1 NK Cell Therapies
  3. 4.1.2 NK Cell Directed Antibodies
  4. 4.2 Global Natural Killer Cell Therapy Sales Value by Type
  5. 4.2.1 Global Natural Killer Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Natural Killer Cell Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Natural Killer Cell Therapy Sales Value Share by Type (2021-2032)
5 Natural Killer Cell Therapy Market by Application
  1. 5.1 Natural Killer Cell Therapy Application Introduction
  2. 5.1.1 Cancer
  3. 5.1.2 Gastrointestinal Diseases
  4. 5.1.3 Others
  5. 5.2 Global Natural Killer Cell Therapy Sales Value by Application
  6. 5.2.1 Global Natural Killer Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Natural Killer Cell Therapy Sales Value by Application (2021-2032)
  8. 5.2.3 Global Natural Killer Cell Therapy Sales Value Share by Application (2021-2032)
6 Natural Killer Cell Therapy Regional Value Analysis
  1. 6.1 Global Natural Killer Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Natural Killer Cell Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Natural Killer Cell Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Natural Killer Cell Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Natural Killer Cell Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Natural Killer Cell Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Natural Killer Cell Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Natural Killer Cell Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Natural Killer Cell Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Natural Killer Cell Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Natural Killer Cell Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Natural Killer Cell Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Natural Killer Cell Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Natural Killer Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 Natural Killer Cell Therapy Country-level Value Analysis
  1. 7.1 Global Natural Killer Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Natural Killer Cell Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Natural Killer Cell Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Natural Killer Cell Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Natural Killer Cell Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Natural Killer Cell Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Natural Killer Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Nektar Therapeutics
  2. 8.1.1 Nektar Therapeutics Company Information
  3. 8.1.2 Nektar Therapeutics Business Overview
  4. 8.1.3 Nektar Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Nektar Therapeutics Natural Killer Cell Therapy Product Portfolio
  6. 8.1.5 Nektar Therapeutics Recent Developments
  7. 8.2 Innate Pharma SA
  8. 8.2.1 Innate Pharma SA Company Information
  9. 8.2.2 Innate Pharma SA Business Overview
  10. 8.2.3 Innate Pharma SA Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Innate Pharma SA Natural Killer Cell Therapy Product Portfolio
  12. 8.2.5 Innate Pharma SA Recent Developments
  13. 8.3 Affimed
  14. 8.3.1 Affimed Company Information
  15. 8.3.2 Affimed Business Overview
  16. 8.3.3 Affimed Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Affimed Natural Killer Cell Therapy Product Portfolio
  18. 8.3.5 Affimed Recent Developments
  19. 8.4 Chipscreen Biosciences
  20. 8.4.1 Chipscreen Biosciences Company Information
  21. 8.4.2 Chipscreen Biosciences Business Overview
  22. 8.4.3 Chipscreen Biosciences Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Chipscreen Biosciences Natural Killer Cell Therapy Product Portfolio
  24. 8.4.5 Chipscreen Biosciences Recent Developments
  25. 8.5 Glycostem Therapeutics
  26. 8.5.1 Glycostem Therapeutics Company Information
  27. 8.5.2 Glycostem Therapeutics Business Overview
  28. 8.5.3 Glycostem Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Glycostem Therapeutics Natural Killer Cell Therapy Product Portfolio
  30. 8.5.5 Glycostem Therapeutics Recent Developments
  31. 8.6 Fate Therapeutics
  32. 8.6.1 Fate Therapeutics Company Information
  33. 8.6.2 Fate Therapeutics Business Overview
  34. 8.6.3 Fate Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fate Therapeutics Natural Killer Cell Therapy Product Portfolio
  36. 8.6.5 Fate Therapeutics Recent Developments
  37. 8.7 Dragonfly Therapeutics
  38. 8.7.1 Dragonfly Therapeutics Company Information
  39. 8.7.2 Dragonfly Therapeutics Business Overview
  40. 8.7.3 Dragonfly Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Dragonfly Therapeutics Natural Killer Cell Therapy Product Portfolio
  42. 8.7.5 Dragonfly Therapeutics Recent Developments
  43. 8.8 Kiadis Pharma
  44. 8.8.1 Kiadis Pharma Company Information
  45. 8.8.2 Kiadis Pharma Business Overview
  46. 8.8.3 Kiadis Pharma Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kiadis Pharma Natural Killer Cell Therapy Product Portfolio
  48. 8.8.5 Kiadis Pharma Recent Developments
  49. 8.9 Nkarta Therapeutics
  50. 8.9.1 Nkarta Therapeutics Company Information
  51. 8.9.2 Nkarta Therapeutics Business Overview
  52. 8.9.3 Nkarta Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nkarta Therapeutics Natural Killer Cell Therapy Product Portfolio
  54. 8.9.5 Nkarta Therapeutics Recent Developments
  55. 8.10 NantKwest
  56. 8.10.1 NantKwest Company Information
  57. 8.10.2 NantKwest Business Overview
  58. 8.10.3 NantKwest Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  59. 8.10.4 NantKwest Natural Killer Cell Therapy Product Portfolio
  60. 8.10.5 NantKwest Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst